GAIN-THERAPEUTICS-SA
23.7.2019 08:32:09 CEST | Business Wire | Press release
Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in central nervous system (CNS) diseases, today announced that together with Dr. Maurizio Molinari from the Institute for Research in Biomedicine, Bellinzona (Switzerland) affiliated to the Università della Svizzera italiana (USI) and Neuro-Sys SAS in Gardanne (France), it has received funding support from Eurostars-2 joint programme with co-funding from the European Union Horizon 2020 research and Innosuisse – Swiss Innovation Agency.
This grant will further strengthen Gain Therapeutics’s novel therapeutic approach for targeting rare diseases in the CNS, where lysosomal misfolded enzymes lead to sever clinical phenotypes, where no treatment is available and/or high unmet medical needs still do afflict patients, families and carers. This funding will support the development of the drugs portfolio of Gain Therapeutics for the treatment of Gaucher Disease, GM1 Gangliosidosis and Parkinson’s Disease.
“We are proud of the Eurostars-2 grant notification, where Gain Therapeutics’ platform technology for identifying structurally targeted allosteric regulators has been very positively evaluated due to: clear unmet medical needs (and namely orphan, rare and defined diseases with a strong neurological need still unmet); novel platform technology developing brain penetrant small molecules able to restore misfolded lysosomal enzyme; a clearly defined path into a significant market; a balanced yet ambitious project with a strong IP estate,” said Dr. Manolo Bellotto, General Manager of Gain Therapeutics SA.
“The excellent ranking of our consortium as 2nd best among over 325 eligible consortia from all over Europe is also a rewarding recognition for our long-standing activity in the field of rare diseases. The transnational collaboration with Gain Therapeutics and Neuro-Sys will hopefully offer the opportunity to translate into the clinics, the research activity performed at the IRB and aiming at understanding how perturbations in protein folding may cause severe diseases” said Dr. Maurizio Molinari, Group leader at the IRB, Bellinzona and Adjunct Professor at the École Polytechnique Fédérale de Lausanne (EPFL).
“The innovative scientific approach of the project has strongly motivated us to get involved. The remarkable ranking at European level clearly demonstrates Europe's interest in developing innovative cures for orphan indications. The collaboration with Gain Therapeutics and IRB on this ambitious project is a great opportunity to develop innovative platforms and to get a better understanding of the mechanisms of these rare diseases.” said Dr. Noelle Callizot, CSO and General Manager of Neuro-Sys SAS.
About Gain Therapeutics SA
Gain Therapeutics SA is a Swiss biotech company specializing in the discovery of new drugs for rare and CNS diseases. The company targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs. Gain Therapeutics SA is developing a new class of compounds: structurally targeted allosteric regulators, identified through its pioneering proprietary platform – SEE-Tx.
https://www.gaintherapeutics.com/
About Institute for Research in Biomedicine
Founded in 2000 in Bellinzona, the IRB is affiliated with the Università della Svizzera italiana, since 2010. IRB hosts 13 research groups studying defense mechanisms to fight infections, tumors and degenerative diseases. With more than 630 publications in main scientific journals, the IRB has gained international recognition as a center of excellence for immunology and cell biology. Molinari’s laboratory investigates the protein quality control processes determining whether a polypeptide should be secreted, retained in the ER, or selected for degradation. Particular emphasis is given to the study of select rare diseases such as α1-antitrypsin deficiency, LSDs and Charcot-Marie-Tooth 1B neuropathy.
About Neuro-Sys
Neuro-Sys is expert in preclinical in vitro models of neurodegenerative and neurological diseases. It has developed specific models to accurately determine the pharmacological profiling of lead compounds and explore their underlying mechanism of action and to determine the therapeutic indication. With a great team of experts in pharmacology and drug development and an innovative proprietary automated medium throughput platform combined with advanced models, it provides predictable results and a unique approach in the neurodegenerative diseases research. The company’s many loyal pharma and biotech customers around the world are the best testimony to the efficiency and reliability of its solution.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190722005034/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Toluna Announces Planned CEO Transition After 25 Years; Founder Frédéric Charles Petit to remain as Board Member, Senior Advisor and Shareholder8.10.2026 16:20:00 CEST | Press release
Toluna, a global leader in consumer insights and market research technology, today announces a planned leadership transition. After 25 years leading the company he founded, Frédéric Charles Petit, Founder and Chief Executive Officer, intends to transition from his role as CEO following the appointment of his successor as part of a carefully planned succession process designed to ensure continuity for clients, employees and partners. Following the transition, Mr. Petit will continue to serve on Toluna's Board of Directors, will remain a significant shareholder of the company, and will take on an ongoing strategic advisory role for areas central to Toluna's next phase of growth. The Board, in close consultation with Mr. Petit, has initiated a structured succession process. A comprehensive transition plan is in place, including a defined handover with Mr. Petit, to ensure continuity for the company’s clients, employees, and partners. The Board expects to confirm the appointment of the com
CSC Wins for Threat Intelligence Innovation in 2026 CyberSecurity Breakthrough Awards8.10.2026 16:00:00 CEST | Press release
3D Domain Security and Global Enforcement recognized for excellence in an information security product CSC, an enterprise-class domain registrar and world leader in detecting and mitigating brand, fraud, domain, and Domain Name System (DNS) threat vectors, today announced that its 3D Domain Security and Global Enforcement solution won for Threat Intelligence Innovation in the 10th annual CyberSecurity Breakthrough Awards. The awards recognize the most innovative companies, products, and technologies driving progress in the global information security industry. CSC’s 3D Domain Security and Global Enforcement solution for the enterprise domain ecosystem combines advanced AI machine learning technology, proprietary domain threat intelligence, expert analysis, and integrated global enforcement. With this technology, organizations can detect, understand, and act on external cyber threats targeting their brand online across social media, search engines, email, and e-commerce websites. By unc
Stonebranch Launches Hybrid Orchestration Control Plane to Provide Governed Reliability in the Agentic Era8.10.2026 15:00:00 CEST | Press release
New capability in Universal Automation Center 8.1 connects automation, AI workflows, autonomous agents, and human approvals in a single governed process. Stonebranch, a leading provider of service orchestration and automation solutions, today announced the Hybrid Orchestration Control Plane, a new solution powered by Stonebranch Universal Automation Center™ (UAC) version 8.1. It lets enterprises run traditional automation, AI tasks, autonomous agents, and human decisions as one end-to-end workflow, with consistent permissions, approvals, service levels, audit trails, and recovery controls. Agents are spreading across the enterprise, but they act without the operational context around each decision: prior approvals, downstream dependencies, and recovery. Alone, they become another disconnected execution environment, with separate controls, fragmented visibility, and custom plumbing. The Hybrid Orchestration Control Plane connects them to existing automation in one governed process: agen
INNIO and Aggreko Extend Strategic Partnership Through 2031, Securing Long-Term Engine Capacity to Meet Growing Global Power Demand8.10.2026 14:37:00 CEST | Press release
INNIO N.V. (Nasdaq: INIO) today announced a substantial extension of its long-standing strategic partnership with Aggreko, a global leader in engineered energy and temperature solutions. The extended agreement, now running through 2031, secures substantial long-term engine capacity for Aggreko while providing INNIO with additional order visibility for medium-power range engines. “Global power demand is rising rapidly, while grid constraints are growing. Together with Aggreko, we are delivering reliable, efficient, and sustainable power solutions that help bridge these gaps and keep customers moving,” said Dr. Olaf Berlien, President and CEO of INNIO. “This agreement secures proven technology and capacity to deliver reliable power wherever and whenever our customers need it,” said Sunny Thakrar, Commercial Director of Aggreko. Under the agreement, INNIO has agreed to provide a minimum of 450 MW of engine capacity in the medium-power range (Jenbacher Type 4) in 2027 and access to agreed
Bacardi Climbs to #32 Among the World’s Top Companies for Women8.10.2026 14:11:00 CEST | Press release
Family-owned Bacardi is highest-ranked spirits company Bacardi Limited has climbed to #32 on the Forbes list of the World’s Top Companies for Women 2026, rising from #60 the previous year and earning a place on the prestigious global ranking for the fifth consecutive year. The family-owned company is the highest-ranked spirits company on this year’s list and ranks #2 in the “Food, Soft Beverages, Alcohol & Tobacco” category. The recognition reflects a continued commitment to creating opportunities, championing career development and cultivating a workplace where people feel valued, empowered and able to do their best work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261008127263/en/ Bacardi celebrates being the highest-ranked spirits company in the Forbes World's Top Companies for Women 2026. “The most meaningful measure of our progress is seeing talented women choose to join Bacardi, build their careers here and advance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom